GERN - Geron Corporation Stock Trading

Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF). “As the only study in refractory MF with overall surv...

Shares of clinical-stage biopharmaceutical company Geron Corporation (NASDAQ: GERN) are dropping sharply on Friday following the company's release of its fourth-quarter and full-year 2020 financial results, as well as some important clinical updates. As of 11:43 a.m. EST, Geron's st...

Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2020 Earnings Call Mar 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2020 Earnings Call Transcript